Results 281 to 290 of about 6,589,084 (383)

Growth Factor for <i>B. Typhosus</i>. V

, 1951
Iwao Arai
openalex   +2 more sources

Time, the final frontier

Molecular Oncology, EarlyView.
This article advocates integrating temporal dynamics into cancer research. Rather than relying on static snapshots, researchers should increasingly consider adopting dynamic methods—such as live imaging, temporal omics, and liquid biopsies—to track how tumors evolve over time.
Gautier Follain, Michal Dibus, Omkar Joshi, Guillaume Jacquemet   +3 more
wiley   +1 more source

Vascular endothelial growth factor A: friend or foe in the pathogenesis of HIV and SARS-CoV-2 infections? [PDF]

Front Cell Infect Microbiol
van der Mescht MA, Steel HC, Anderson R, Rossouw TM.   +3 more
europepmc   +1 more source

STUDIES ON THE NUTRITIONAL REQUIREMENTS OF BACTERIA VII. PYRIDINE-3-SULFONIC ACID AS A GROWTH FACTOR

, 1952
Den’ichi Mizuno, Tomie Nojima
openalex   +2 more sources

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

Prognostic Correlation of Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor with Radiological Tumor Size in Pediatric Nephroblastoma and Neuroblastoma: A Prospective Study.

J Indian Assoc Pediatr Surg
Kanneganti P, Kumar B, Mathew P, Agarwal V, Yadav R, Mandelia A, Upadhyay VD.   +6 more
europepmc   +1 more source

The Possible Role of Metformin and Fibroblast Growth Factor-21 in Multiple Sclerosis Neuropathology: Birds of a Feather Flock Together. [PDF]

Eur J Neurosci
Abulaban AA, Al-Kuraishy HM, Al-Gareeb AI, Ahmed EA, Alruwaili M, Alexiou A, Papadakis M, El-Saber Batiha G.   +7 more
europepmc   +1 more source

Microglial reprogramming: a potential new frontier in enhancing immunotherapy for melanoma brain metastasis

Molecular Oncology, EarlyView.
Microglia act as tumor suppressors during brain metastasis colonization but shift to a tumor‐promoting role after melanoma brain metastases form. NF‐κB/RelA signaling emerges as a key driver of this phenotypic shift. Targeting this pathway reprograms microglia into a pro‐inflammatory state, enhancing antitumor immunity and immune checkpoint inhibitor ...
Noam Savion‐Gaiger, Dorin Bar‐Ziv, Harriet Kluger   +2 more
wiley   +1 more source

The Vascular Endothelial Growth Factor-A121/Vascular Endothelial Growth Factor-A165 Ratio as a Predictor of the Therapeutic Response to Immune Checkpoint Inhibitors in Gastric Cancer. [PDF]

Cancers (Basel)
Hamada Y, Tanoue K, Arigami T, Yamakuchi M, Okawa M, Matsushita D, Takenouchi K, Yamada S, Maywar DN, Nakayama C, Oyama Y, Higashi S, Fujisaki C, Hozaka Y, Kita Y, Hashiguchi T, Ohtsuka T.   +16 more
europepmc   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source